[{"id":"0722b240-7848-480e-91ab-a7a7c502ac66","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445843","created_at":"2022-07-06T14:54:25.537Z","updated_at":"2024-07-02T16:34:27.361Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression \u003c 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","source_id_and_acronym":"NCT05445843","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • KRAS • STK11","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS G12C + PD-L1 expression","tags":["PD-L1 • KRAS • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS G12C + PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e opnurasib (JDQ443)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/06/2022","start_date":" 12/06/2022","primary_txt":" Primary completion: 11/02/2026","primary_completion_date":" 11/02/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-06-11"}]